What is HC Wainwright’s Estimate for DWTX FY2030 Earnings?

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – HC Wainwright issued their FY2030 EPS estimates for shares of Dogwood Therapeutics in a research note issued to investors on Thursday, March 19th. HC Wainwright analyst S. Lee forecasts that the company will earn $2.29 per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share.

Dogwood Therapeutics (NASDAQ:DWTX) last released its earnings results on Wednesday, March 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.96.

A number of other research firms have also recently issued reports on DWTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. Wall Street Zen lowered Dogwood Therapeutics to a “strong sell” rating in a research report on Saturday, December 13th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Stock Up 10.7%

Dogwood Therapeutics stock opened at $3.00 on Friday. Dogwood Therapeutics has a 12 month low of $2.60 and a 12 month high of $9.50. The stock has a market cap of $100.20 million, a P/E ratio of -0.16 and a beta of 1.90. The company’s fifty day simple moving average is $2.95 and its 200-day simple moving average is $4.66.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is currently owned by institutional investors and hedge funds.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.